Emergent Biosolutions (EBS) said Thursday that it has been awarded two contract options worth $67.4 million by the US government to obtain additional treatment courses of Tembexa to support smallpox preparedness.
The options are part of Emergent's existing 10-year contract, which has a maximum potential value of $568 million.
Price: 6.00, Change: +0.06, Percent Change: +1.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.